Effective MAPK Inhibition is critical for therapeutic responses in colorectal cancer with BRAF mutations

Leanne G Ahronian; Ryan B Corcoran

doi:10.1080/23723556.2015.1048405

Effective MAPK Inhibition is critical for therapeutic responses in colorectal cancer with BRAF mutations

Mol Cell Oncol. 2015 May 21;3(1):e1048405. doi: 10.1080/23723556.2015.1048405. eCollection 2016 Jan.

Authors

Leanne G Ahronian¹, Ryan B Corcoran¹

Affiliation

¹ Massachusetts General Hospital Cancer Center, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA.

Abstract

RAF inhibitor monotherapy is ineffective in BRAF-mutant colorectal cancer (CRC) but RAF inhibitor combinations have demonstrated improved efficacy, likely through superior suppression of MAPK signaling. The first identified mechanisms of acquired resistance to these combinations all promote MAPK reactivation, underscoring the MAPK pathway as a critical target in BRAF-mutant CRC.

Keywords: BRAF; BRAF inhibitor; Clinical trials; ERK inhibitor; MAPK; colorectal cancer; resistance.

Abstract

Grants and funding